Novartis Rhapsido® receives European Commission approval
Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 & 2 studies of highly…
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study1 40.7% of patients on Fabhalta…
Skydio opens research office for autonomous drones in Zurich
The U.S. drone manufacturer Skydio has opened a research and development office in Zurich. Skydio Switzerland GmbH focuses…
Novartis announces expansion of community health programs
Strengthens three community health models spanning community‑embedded care, earlier intervention and data‑driven population healthScales program footprint from 11…
The Power of PRECISION: Using AI to Navigate the Future of Prostate Cancer Care
Precision medicine treatment options in metastatic prostate cancer are expanding rapidly—and while it allows care to be tailored…
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
Cosentyx is the only IL‑17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS…
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
Strengthens three community health models spanning community‑embedded care, earlier intervention and data‑driven population healthScales program footprint from 11…
Switzerland Innovation Park Zurich sichert sich 445 Millionen für Neubauten
Auf dem Militärflugplatz Dübendorf entsteht der Switzerland Innovation Park Zurich – ein Campus für angewandte Forschung, technologische Entwicklung…
Novartis announces expansion of community health programs
Strengthens three community health models spanning community‑embedded care, earlier intervention and data‑driven population healthScales program footprint from 11…
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
Strengthens three community health models spanning community‑embedded care, earlier intervention and data‑driven population healthScales program footprint from 11…
Innovation to support modern healthcare development
Laboratory automation is bringing early diagnosis, improving the quality of healthcare, and reducing the burden on the healthcare…
Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites…